Work

Breast cancer cells survive chemotherapy by activating targetable immune-modulatory programs characterized by PD-L1 or CD80

Year: 2022

Type: article

Source: Nature Cancer

DOI: 10.1038/s43018-022-00466-y

Authors: Ashkan Shahbandi, Fang-Yen Chiu, Nathan A. Ungerleider, Raegan Kvadas, Zeinab Mheidly, Meijuan J. S. Sun, Di Tian, Daniel A. Waizman, Ashlyn Y. Anderson, Heather L. Machado, Zachary F. Pursell, Sonia G. Rao, James G. Jackson

Institutions: Tulane University, Yale University

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: U.S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute, National Institute of General Medical Sciences, National Institute of Environmental Health Sciences, National Center for Advancing Translational Sciences

Awards: G1271853457, NRSA Training Core, Kinase signaling during mammary tumor initiation, G808129063, Mentoring Translational Researchers in Louisiana, Genotoxic stress response and mutagenesis in normal tissues of mice deficient in homology directed repair, University of Colorado Cancer Center Support Grant, Louisiana Clinical and Translational Science Center, Investigation of human DNA polymerase epsilon variants, Targeting mechanisms of immune evasion in chemotherapy-induced senescent cells

OpenAlex ID: W4310939814

FWCI: 7.319

Cites: 73

Cited by: 84

Related to: 10